2021
Tumor suppressor p53 regulates intestinal type 2 immunity
Chang C, Wang J, Zhao Y, Liu J, Yang X, Yue X, Wang H, Zhou F, Inclan-Rico J, Ponessa J, Xie P, Zhang L, Siracusa M, Feng Z, Hu W. Tumor suppressor p53 regulates intestinal type 2 immunity. Nature Communications 2021, 12: 3371. PMID: 34099671, PMCID: PMC8184793, DOI: 10.1038/s41467-021-23587-x.Peer-Reviewed Original ResearchConceptsType 2 immunityRole of p53Parasitic infectionsInnate lymphoid cell responsesLymphoid cell responsesImmune integrityInfection of parasitesNippostrongylus brasiliensisTuft cellsCell responsesImmunityInfectionTritrichomonas murisTumor suppressor p53P53Unrecognized functionTumor suppressionSuppressor p53Critical triggerCritical roleCell circuitRoleResponse
2020
The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC
Brown M, Zhang W, Yan D, Kenath R, Le L, Wang H, Delitto D, Ostrov D, Robertson K, Liu C, Pham K. The role of survivin in the progression of pancreatic ductal adenocarcinoma (PDAC) and a novel survivin-targeted therapeutic for PDAC. PLOS ONE 2020, 15: e0226917. PMID: 31929540, PMCID: PMC6957139, DOI: 10.1371/journal.pone.0226917.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaTypes of cancerDuctal adenocarcinomaSurvivin expressionSurvivin inhibitorClinical response rateNovel survivin inhibitorHalf of patientsElevated survivin expressionLower patient survivalPancreatic tumor microenvironmentPotential therapeutic targetExpression of survivinRole of survivinField of oncologyPancreatic cancer linesImmunotherapeutic approachesPatient survivalUntreated cohortTherapeutic responseInhibitor of survivinTreatment resistancePDAC progressionEffective treatmentTumor cell migration
2013
SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion
Chen X, Wang H, Bajaj K, Zhang P, Meng Z, Ma D, Bai Y, Liu H, Adams E, Baines A, Yu G, Sartor M, Zhang B, Yi Z, Lin J, Young S, Schekman R, Ginsburg D. SEC24A deficiency lowers plasma cholesterol through reduced PCSK9 secretion. ELife 2013, 2: e00444. PMID: 23580231, PMCID: PMC3622177, DOI: 10.7554/elife.00444.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsApolipoproteins ECell Line, TumorCholesterolCOP-Coated VesiclesDown-RegulationDyslipidemiasEndoplasmic ReticulumEpistasis, GeneticGenotypeHEK293 CellsHumansLiverMice, 129 StrainMice, Inbred C57BLMice, KnockoutMutationPhenotypeProprotein Convertase 9Proprotein ConvertasesProtein TransportReceptors, LDLSerine EndopeptidasesTransfectionVesicular Transport ProteinsConceptsEndoplasmic reticulumCOPII vesicle formationCargo recruitmentCOPII vesiclesCargo proteinsEukaryotic cellsCargo selectivitySecretory pathwaySEC24AEfficient exitUnappreciated heterogeneityNegative regulatorSecretory proteinsVesicle formationPCSK9 secretionComplete genetic deficiencyGenetic deficiencyLDLR levelsProteinVesiclesFundamental roleNormal survivalPartial overlapRecruitmentSEC24B